Cardinal Health, Inc.
Healthcare Distribution / Medical DistributionFounded 1971- Updated July 2025
Reviewed by Swet Parvadiya
Last reviewed: July 2025
CorpDigest
Cardinal Health, Inc.
Financial Performance
Last reviewed: July 2025 · By Swet Parvadiya
Revenue
$222.6B
Market Cap
$48.2B
Net Income
$1.6B
Employees
48,000
Cardinal Health lost $38.1 billion in annual revenue — roughly 17% of its total — when OptumRx chose not to renew its pharmaceutical distribution contract in June 2024. Cardinal Health generated $222.6 billion in fiscal 2025 revenue by functioning as one of the three dominant pharmaceutical wholesalers in the United States, alongside McKesson and Cencora. The markup is thin — gross margin of just 3.67% on $222.6 billion in revenue. Together, the math produces $8.17 billion in gross profit. Revenue of $222.6 billion in fiscal 2025 represents a decline from $226.8 billion in fiscal 2024, primarily reflecting the OptumRx contract expiration. The gross margin improvement to 3.57% from 3.21% on lower revenue confirms management's assertion that the OptumRx business was margin-dilutive. Net income of $1.569 billion on $222.6 billion in revenue — a 0.7% net margin — is characteristic of the pharmaceutical distribution model. The Integrated Oncology Network, GI Alliance, Advanced Diabetes Supply Group ($1.1 billion), and Solaris Health acquisitions represent a deliberate pivot toward healthcare services businesses that generate margins far above the 1.10% segment profit margins in core pharmaceutical distribution. Revenue history: $181 billion in 2022, $205 billion in 2023, $227 billion in 2024, $222.6 billion in 2025. The Allegiance Healthcare acquisition in 1999 for $2.2 billion added medical products distribution to the pharmaceutical focus, briefly diversifying the model. Cardinal Health, along with McKesson and AmerisourceBergen, agreed to a $21 billion settlement in 2021 covering its role in distributing opioids despite warning signs about diversion.
Revenue Trend Analysis
YoY Change
-1.9%
3-Year CAGR
+7.1%
Peak Year
2024
Trend
Mostly Growing
Cardinal Health, Inc. has reported revenue across 4 fiscal years, compounding at +7.1% annually over 3 years. The most recent year saw a 1.9% decline versus the prior year. Revenue peaked in 2024 at $226.8B. Out of 3 reported periods, 2 showed growth and 1 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2025 | $222.6B | $1.6B | -1.9% |
| FY2024 | $226.8B | — | +10.7% |
| FY2023 | $205.0B | — | +13.0% |
| FY2022 | $181.3B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Cardinal Health's $1.57 billion net income on $222.6 billion revenue represents 0.7% net margin — characteristic of pharmaceutical distribution where thin spreads on enormous volumes generate meaningful absolute profits despite low percentage margins. Operating margins of 0.8-1.0% similarly reflect industry economics, with margins comparable to McKesson and Cencora. Cardinal's profitability supports continued dividend payments ($1.95 annually, 1.7% yield), capital allocation toward debt reduction, and selective acquisitions, plus mandatory opioid settlement payments of $300-400 million annually through 2038. Operating cash flow generation of $2-3 billion annually provides capital allocation flexibility despite thin margins. Earnings growth has been modest (low single digits) reflecting mature distribution business with limited organic growth above pharmaceutical industry baseline growth.
Cardinal Health accrued approximately $6 billion in opioid settlement obligations payable over 18 years (through 2038), structured as approximately $300-400 million annual payments that affect cash flow but remain manageable within current operating profitability. The settlement structure was deliberately designed to enable continued operations while providing meaningful compensation to opioid epidemic victims, with the long payment period spreading impact rather than triggering operational crisis. Cardinal's compliance with payment obligations has been consistent, and the company has implemented enhanced opioid distribution monitoring including suspicious order detection systems, prescription tracking, and pharmacy ordering pattern analysis. Additional opioid-related lawsuits continue against Cardinal Health and pharmaceutical industry participants, though the major Big Three settlement has stabilised most liability. The opioid impact represents significant historical financial penalty but doesn't threaten company's long-term operational sustainability.
Cardinal Health allocates capital across dividend payments (1.7% yield supporting income-focused investors), share buybacks ($500+ million authorised annually when conditions favorable), opioid settlement obligations ($300-400 million annually), and operational reinvestment, with limited capacity for transformational acquisitions given debt levels and ongoing legal obligations. The capital framework reflects pharmaceutical distribution's mature business model — modest organic growth, stable cash generation, and limited reinvestment opportunities supporting consistent shareholder returns. Debt management has been prioritised given significant absolute debt levels ($8 billion) and credit rating considerations, with the company maintaining investment-grade ratings supporting financial flexibility. Future capital allocation may shift toward growth investment if opioid obligations stabilise and operating margin expansion creates incremental capital availability.
Cardinal Health faces significant customer concentration with major customers including CVS Health (major pharmacy contract), Walmart, Kroger, and various hospital systems, with top 10 customers representing approximately 50% of total revenue. The 2024 OptumRx contract loss demonstrated this risk's reality — single large customer departure can affect revenue and profitability substantially. Customer concentration creates ongoing pricing pressure as major customers regularly renegotiate contracts to capture cost reductions, plus operational complexity in serving customers with different requirements. Cardinal's competitive response includes building specialty pharmaceutical capabilities differentiating from generic distribution competition, expanding services beyond pure distribution (managed care, patient services), and pursuing customer diversification through independent pharmacy and hospital channel growth. The concentration challenge will continue given pharmacy industry consolidation creating fewer larger customers.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Cardinal Health, Inc. Revenue & Financials." CorpDigest, https://corpdigest.com/company/cardinal-health/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Cardinal Health, Inc. reported $223B in revenue (FY2025).</strong><br>Source: <a href="https://corpdigest.com/company/cardinal-health/financials" target="_blank" rel="noopener">CorpDigest — Cardinal Health, Inc. financials</a></div>